2018-10-24T08:55:02-05:00 2017-12-31 520982413 GROSS MENDELSOHN & ASSOCIATES PA 36 SOUTH CHARLES ST 18TH FLOOR BALTIMORE MD 21201 990 2017-01-01 954132414 CURESEARCH FOR CHILDREN'S CANCER CURE 2402352200 4600 EAST WEST HIGHWAY NO 600 BETHESDA MD 20814 KAY KOEHLER CEO 2402352200 2018-10-24 1 JAMES E CRISP P00025401 4106855512 2018-10-22 64.132.215.242 2018-10-24 09:54:53 ED P AC7F7C529038E5307F9A18346D290F0CDD176BDF E55DBCF77934BBFFDEFB4763FBB896FCA5EDC45D 2017 2018-06-14 16:35:46Z KAY KOEHLER 4600 EAST WEST HIGHWAY NO 600 BETHESDA MD 20814 5627580 0 X WWW.CURESEARCH.ORG X 1987 CA CURESEARCH FUNDS AND SUPPORTS CHIDLREN'S CANCER RESEARCH AND PROVIDES EDUCATION AND RESOURCES TO ALL THOSE AFFECTED BY CHILDREN'S CANCER. 14 14 37 178 0 0 2598912 1796520 0 0 230809 188364 2458140 2508583 5287861 4493467 2477612 1404136 0 0 2935510 2642196 0 0 1464318 1141129 1137473 6554251 5183805 -1266390 -690338 6030880 5314368 560162 351872 5470718 4962496 X CURESEARCH'S MISSION IS TO FUND AND SUPPORT TARGETED AND INNOVATIVE CANCER RESEARCH WITH MEASURABLE RESULTS, AND TO BE THE AUTHORITATIVE SOURCE OF INFORMATION AND RESOURCES FOR ALL THOSE AFFECTED BY CHILDREN'S CANCER.(SEE SCHEDULE O FOR CONTINUATION)CURESEARCH SUPPORTS CHILDHOOD CANCER RESEARCH AT ALL STAGES ALONG THE RESEARCH CONTINUUM, FROM FELLOWSHIPS THAT ACCELERATE THE CAREERS OF YOUNG RESEARCHERS TO MULTI-MILLION DOLLAR GRANTS THAT SUPPORT RESEARCH TEAMS DEVELOPING POTENTIAL NEW TREATMENTS, TO CLINICAL TRIAL AWARDS THAT ENABLE HOSPITALS TO ENROLL CHILDREN BEING TREATED TODAY. IT PROVIDES EDUCATIONAL RESOURCES TO PARENTS AND CAREGIVERS, INCLUDING PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT, PROCEDURAL VIDEOS, AND PARENT WEBINARS. CURESEARCH ALSO RAISES FUNDS THROUGH INDIVIDUALS, CORPORATIONS, PRIVATE FOUNDATIONS, AND SPECIAL EVENTS. 0 0 3027725 1404136 CURESEARCH SUPPORTS RESEARCH EFFORTS TO IMPROVE TREATMENTS AND FIND CURES FOR CHILDREN'S CANCER. THROUGH COMPETITIVE GRANT MAKING INITIATIVES, CURESEARCH FUNDS RESEARCH TEAMS ACROSS THE COUNTRY THAT STUDY MORE THAN 13 TYPES OF CANCER IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH THE GOAL OF IMPROVING CURRENT TREATMENTS, DEVELOPING NEW THERAPIES, AND UNDERSTANDING THE BIOLOGY OF MORE PEDIATRIC CANCER DISEASE TYPES. CURESEARCH FUNDS RESEARCH AT ALL STAGES OF THE PIPELINE, INCLUDING BASIC SCIENCE, TRANSLATIONAL RESEARCH, CLINICAL TRIAL DEVELOPMENT, AND THE TESTING OF NEW CANCER THERAPIES. THIS RESEARCH IMPACTS OVER 14,900 CHILDREN DIAGNOSED WITH CANCER EACH YEAR WITH THE LONG-TERM GOAL OF DEVELOPING THERAPIES THAT CURE CHILDREN TODAY WITHOUT HARMING THEM TOMORROW. (SEE SCHEDULE O FOR CONTINUATION)CURESEARCH FUNDS CLINICAL TRIALS ACROSS THE COUNTRY. CLINICAL TRIALS ENSURE THAT CHILDREN WITH CANCER GET ACCESS TO THE BEST CURRENT TREATMENTS. THE DATA COLLECTED FROM CLINICAL TRIALS ENABLES RESEARCHERS TO ACHIEVE A BETTER UNDERSTANDING OF CANCER BIOLOGY AND GUIDES THE DEVELOPMENT OF NEW TREATMENTS AND TREATMENT PROTOCOLS. CLINICAL TRIALS ARE COSTLY FOR HOSPITALS, WHICH RELY ON SUPPORT FROM CURESEARCH AND OTHER ORGANIZATIONS TO BE ABLE TO PROVIDE TREATMENT FOR CHILDREN WITH CANCER. EACH YEAR, ALMOST 10,000 CHILDREN ARE ENROLLED IN CLINICAL TRIALS. IN ADDITION TO FUNDING RESEARCH, CURESEARCH ALSO PROVIDES INFORMATION AND RESOURCES TO PATIENTS AND FAMILIES. CURESEARCH RESOURCES INCLUDE CURESEARCH.ORG, AN ONLINE RESOURCE WITH PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT FOR CHILDRENS CANCER; A LIBRARY OF PROCEDURE VIDEOS THAT DEMONSTRATE CANCER TREATMENTS FOR CHILDREN; AND WEBINARS AND GUIDES FOR PARENTS ON COPING WITH CANCER, FINDING COMMUNITY SUPPORT, AND REINTEGRATING A CHILD INTO SCHOOL AND SOCIAL ENVIRONMENTS. THESE RESOURCES AID ABOUT 28,500 INDIVIDUALS EACH YEAR. 3027725 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 16 0 1 37 1 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X X MANAGEMENT 2402352200 4600 EAST WEST HIGHWAY BETHESDA MD 20814 STUART SIEGEL MD CHAIR 1.00 X X 0 0 0 MICHAEL MILLER ESQUIRE SECRETARY 1.00 X X 0 0 0 WALTER B ROSE TREASURER 1.00 X X 0 0 0 LISA LIPSKY DIRECTOR 1.00 X X 0 0 0 HANK ADAMS DIRECTOR 1.00 X 0 0 0 PAULA CARTER DIRECTOR 1.00 X 0 0 0 CASON CARTER DIRECTOR 1.00 X 0 0 0 MIKE CARTER DIRECTOR 1.00 X 0 0 0 ANNIE GOULD DIRECTOR 1.00 X 0 0 0 CARLEEN HAWN DIRECTOR 1.00 X 0 0 0 MATT KELLY DIRECTOR 1.00 X 0 0 0 RICHARD J O'REILLY MD DIRECTOR 1.00 X 0 0 0 RAPHAEL ROUSSEAU MD PHD DIRECTOR 1.00 X 0 0 0 KATHY WANNER DIRECTOR 1.00 X 0 0 0 LAURA THRALL CEO/PRESIDENT 40.00 X 309444 0 11283 KAY KOEHLER CHIEF DEVELOPMENT OFFICER 40.00 X 115236 0 3406 KATHARINE BURKE VP OPERATIONS & FINANCE 40.00 X 161525 0 9151 KELLI WRIGHT NATL DIRECTOR, BUSINESS DEVELOPMENT 40.00 X 102207 0 12547 SARITA SASTRY NATL DIRECTOR, RESEARCH & PROGRAMS 40.00 X 100670 0 7830 789082 0 44217 5 0 1 0 0 1796520 71556 1796520 133702 133702 1043664 989002 54662 54662 54662 2616819 145111 2471708 2471708 MISCELLANEOUS REVENUE 541700 36875 36875 36875 4493467 0 0 2696947 1404136 1404136 610047 261862 221159 127026 1657182 798259 128905 730018 46469 22327 4258 19884 169048 80970 21016 67062 159450 74719 24105 60626 56134 56134 86078 86078 23576 23576 144654 79797 18451 46406 59478 27871 8992 22615 216935 106336 31998 78601 207362 97170 31348 78844 151824 20245 15795 115784 56773 28247 8439 20087 28992 13586 4383 11023 BANK FEES 79398 2957 76441 OTHER PERSONNEL EXPENSE 18761 8725 2956 7080 LICENSES AND FEES 7417 3475 1121 2821 MISCELLANEOUS 91 91 5183805 3027725 691762 1464318 155453 455098 281601 201178 108658 143138 376578 220474 90834 33675 300650 245279 84362 55371 4760958 4180632 172436 24802 6030880 5314368 259620 226950 35406 42070 265136 82852 560162 351872 X 690493 416635 2280225 3045861 2500000 1500000 5470718 4962496 6030880 5314368 -690338 182116 0 X X 0 1 X 1 0 X 2291816 2132029 3341030 2598912 1796520 12160307 2291816 2132029 3341030 2598912 1796520 12160307 1566191 10594116 152815 116282 173280 158815 133702 734894 137375 41814 35 3385 36875 219484 13114685 17059776 0.80780 0.96420 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2013 AMOUNT: $ 137,375. 2014 AMOUNT: $ 41,814. 2015 AMOUNT: $ 35. 2016 AMOUNT: $ 3,385. 2017 AMOUNT: $ 36,875. 2969834 277370 1094971 2152233 2969455 146915 146536 2969834 3095943 -25488 101000 2969455 2982976 165038 52071 3095943 2800368 300360 117752 2982976 0.69700 0.30300 0 0 171696 116325 55371 110409 110409 0 18545 18545 0 55371 DEFERRED RENT 82852 82852 X 4652007 182116 182116 4469891 23576 23576 4493467 5160229 0 5160229 23576 23576 5183805 PART V, LINE 4: DONOR RESTRICTED ENDOWMENT FUNDS HAVE BEEN ESTABLISHED TO ADVANCE PEDIATRIC CANCER RESEARCH BY DISEASE, BY MEDICAL DISCIPLINE, OR THROUGH RESEARCH FELLOWSHIPS. PART X, LINE 2: IN ACCORDANCE WITH FIN 48 (ASC 740), INCOME TAXES, MANAGEMENT EVALUATED ITS ACTIVITIES AND DETERMINED THAT CURESEARCH HAD TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO OR DISCLOSURE IN THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THE ACCOUNTING STANDARD. IN GENERAL, THE ORGANIZATION'S FEDERAL EXEMPT ORGANIZATION TAX RETURNS ARE SUBJECT TO EXAMINATION BY THE IRS, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THE RETURNS ARE FILED. PART V, ENDOWMENT FUNDS, LINE 1E DURING 2017, THE DONOR OF A $1,000,000 ENDOWMENT FUND AGREED TO RELEASE THE RESTRICTION TO HOLD THE ORGINAL GIFT AS AN ENDOWMENT. THE $1,000,000 IS NOW FULLY EXPENDABLE BUT IS RESTRICTED TO THE CATAPULT INITIATIVE. THEREFORE THIS $1,000,000 HAS BEEN INCLUDED ON LINE 1E AS AN EXPENDITURE IN ORDER TO REMOVE IT FROM THE ENDOWMENT SCHEDULE. 0 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT FOR CANCER RESEARCH GRANT FOR CANCER RESEARCH 492946 0 0 0 0 0 0 492946 0 492946 UNITED KINGDOM THERAPEUTIC 492946 WIRE TRANSFER 1 0 0 0 0 0 0 PART I, LINE 2: PROGRESS REPORTS ARE MONITORED WALK/RUN EVENT 2616819 2616819 33435 21460 17734 72482 2616819 2616819 33435 21460 17734 72482 145111 2471708 1 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BP412 BOSTON MA 022155450 422263040 501 (C) (3) 160000 THERAPEUTIC METHODIST CHILDREN'S HOSPITAL 4000 24TH STREET LUBBOCK TX 79410 752428911 501 (C) (3) 10000 THERAPEUTIC SEATTLE CHILDREN'S HOSPITAL FOUNDATION PO BOX 24728 SEATTLE WA 98124 910564748 501 (C) (3) 75000 THERAPEUTIC STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 94144 941156365 501 (C) (3) 208543 THERAPEUTIC TEDDY BEAR CANCER FOUNDATION 3892 STATE STREET SUITE 220 SANTA BARBARA CA 93105 141872081 501 (C) (3) 10000 THERAPEUTIC YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501 (C) (3) 75000 THERAPEUTIC ASSOC OF PEDIATRIC HEMATOLOGYONCOLOGY NURSES PO BOX 3781 OAK BROOK IL 60522 237446224 501 (C) (3) 10000 THERAPEUTIC MEMORIAL SLOAN KETTERING CANCER CENTER 633 THIRD AVE 28TH FLOOR NEW YORK NY 10017 131924236 501 (C) (3) 338254 THERAPEUTIC UNIVERSITY OF ILLINOIS 809 S MARSHFIELD AVE 502 MB MC 551 CHICAGO IL 60612 376000511 501 (C) (3) 10000 THERAPEUTIC 9 PART I, LINE 2: CURESEARCH'S MANAGEMENT WILL REQUEST PERIODIC REPORTS AND STATUS UPDATES OF ITS GRANT AWARDS THROUGHOUT THE YEAR. X X 0 1 0 0 0 0 0 0 0 LAURA THRALL CEO/PRESIDENT 309444 0 0 0 0 0 5400 0 5883 0 320727 0 0 0 KATHARINE BURKE VP OPERATIONS & FINANCE 161525 0 0 0 0 0 3268 0 5883 0 170676 0 0 0 PART I, LINE 4B CURESEARCH HAD ADOPTED A DEFERRED COMPENSATION PLAN UNDER INTERNAL REVENUE CODE 457(B) FOR THE BENEFIT OF CERTAIN KEY EMPLOYEES. UNDER THE PLAN, PARTICIPATING EMPLOYEES COULD ELECT TO DEFER A PORTION OF THEIR COMPENSATION ON A PRE-TAX BASIS INTO THE PLAN (UP TO PRESCRIBED LIMITS UNDER THE IRC). CURESEARCH COULD MAKE DISCRETIONARY CONTRIBUTIONS TO THE PLAN FOR EACH PARTICIPATING EMPLOYEE. DURING 2017, THIS PLAN WAS TERNMINATED AND ALL ASSETS WERE DISTRIBUTED TO THE RESPECTIVE PARTICIPATING EMPLOYEE. A DISTRIBUTION OF $75,489 WAS PAID TO LAURA THRALL, CEO/PRESIDENT. X 5 31051 FAIR MARKET VALUE X EVENT MANAGEMENT / PROMOTION SERVICES 1 40505 FAIR MARKET VALUE 0 0 1 PART I, LINE 32B: THE ORGANIZATION USES STOCK BROKERS TO SELL GIFTS OF PUBLICLY TRADED STOCK. FORM 990, PART VI, SECTION A, LINE 2 THE MEMBERSHIP OF CURESEARCH'S BOARD OF DIRECTORS INCLUDES MIKE AND PAULA CARTER (HUSBAND AND WIFE) AND MARY AND RICHARD PAYNE (HUSBAND AND WIFE). FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION RETAINS AN OUTSIDE CPA TO PREPARE THE IRS FORM 990. PRIOR TO FILING, THE COMPLETED RETURN IS REVIEWED IN DETAIL BY THE CEO/PRESIDENT AND PRESENTED TO THE EXECUTIVE COMMITTEE OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR, ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES ARE PROVIDED WITH THE CONFLICT OF INTEREST POLICY FOR REVIEW AND ARE REQUIRED TO SIGN AND SUBMIT THE ANNUAL CONFLICT OF INTEREST STATEMENT. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE CEO WAS DETERMINED BY THE BOARD CHAIR AFTER CONSIDERATION OF COMPATIBILITY DATA PROVIDED BY THE HUMAN RESOURCES DEPARTMENT. THE BOARD APPROVED THE BOARD CHAIR'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 CURESEARCH'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. CURESEARCH'S FINANCIAL STATEMENTS AND FORM 990S ARE AVAILABLE ON ITS WEBSITE - CURESEARCH.ORG 990 PART VII, LINE 2C PROCESS HAS NOT CHANGED FROM PRIOR YEAR